Subscribe
hynci-istockphoto-com-dollars-cash-
hynci / iStockphoto.com
2 July 2018Americas

AbbVie and Besins to pay FTC $448m in sham litigation case

Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission ( FTC) $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

More on this story

Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?